KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Total Debt (2016 - 2020)

Historic Total Debt for Nektar Therapeutics (NKTR) over the last 10 years, with Q1 2020 value amounting to $508.9 million.

  • Nektar Therapeutics' Total Debt rose 10572.87% to $508.9 million in Q1 2020 from the same period last year, while for Mar 2020 it was $508.9 million, marking a year-over-year increase of 10572.87%. This contributed to the annual value of $502.9 million for FY2019, which is 10364.08% up from last year.
  • According to the latest figures from Q1 2020, Nektar Therapeutics' Total Debt is $508.9 million, which was up 10572.87% from $502.9 million recorded in Q4 2019.
  • In the past 5 years, Nektar Therapeutics' Total Debt ranged from a high of $508.9 million in Q1 2020 and a low of $242.1 million during Q1 2016
  • In the last 5 years, Nektar Therapeutics' Total Debt had a median value of $245.6 million in 2018 and averaged $275.9 million.
  • As far as peak fluctuations go, Nektar Therapeutics' Total Debt surged by 70.71% in 2019, and later skyrocketed by 10572.87% in 2020.
  • Over the past 5 years, Nektar Therapeutics' Total Debt (Quarter) stood at $243.5 million in 2016, then rose by 0.72% to $245.2 million in 2017, then rose by 0.71% to $247.0 million in 2018, then surged by 103.64% to $502.9 million in 2019, then grew by 1.2% to $508.9 million in 2020.
  • Its Total Debt was $508.9 million in Q1 2020, compared to $502.9 million in Q4 2019 and $248.3 million in Q3 2019.